Preoperative LMR and Serum CA125 Level as Risk Factors for Advanced Stage of Ovarian Cancer

被引:11
|
作者
Tang, Ying [1 ]
Hu, Hui-Quan [1 ]
Tang, Ya-Lan [1 ]
Tang, Fang-Xiang [2 ]
Zheng, Xue-Mei [2 ]
Deng, Li-Hong [2 ]
Yang, Ming-Tao [1 ]
Yin, Su [1 ]
Li, Jun [1 ]
Xu, Fan [1 ]
机构
[1] North Sichuan Med Coll, Affiliated Nanchong Cent Hosp, Dept Obstet & Gynecol, Nanchong, Sichuan, Peoples R China
[2] North Sichuan Med Coll, Nanchong, Sichuan, Peoples R China
来源
JOURNAL OF CANCER | 2021年 / 12卷 / 19期
关键词
Ovarian cancer; lymphocyte-to-monocyte ratio (LMR); CA125; International Federation of Gynecology and Obstetrics (FIGO); stage; combine; TUMOR-ASSOCIATED MACROPHAGES; EPITHELIAL OVARIAN; METASTASIS; SURVIVAL; SYSTEM;
D O I
10.7150/jca.62090
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study was to analyze the relationships between lymphocyte-to-monocyte ratio (LMR) alone or combined with serum CA125 (COLC) and advanced stage of ovarian cancer (OC). Methods: The receiver-operating characteristic (ROC) curves of LMR, CA125, and COLC staging OC were constructed by a retrospective study. Furthermore, a binary logistic regression model was used to assay the independent risk factors for OC staging. Results: Two hundred and twenty-five patients with OC were identified in this cohort. Eighty-five OC patients were diagnosed at an early stage, and 140 OC patients were diagnosed at an advanced stage. The median of LMR in the early stage was higher than that in advanced stage (4.4 vs. 2.8), and the median of serum CA125 was lower than that in advanced stage (80 U/mL vs. 251.3 U/mL). Multivariate logistic regression LMR <= 3.7 (OR=0.299, 95% CI: 0.093-0.962, P=0.043) and CA125>95.7 U/mL (OR=4.317, 95% CI: 1.436-12.977, P=0.009) were risk factors for stage of advanced OC whether presence or absence of malignant ascites. Furthermore, the area under the curve of COLC was higher than that of LMR (0.782 vs. 0.732) or serum CA125 (0.782 vs. 0.708) in staging OC. The specificity of COLC was higher than that of LMR (87.1% vs. 70.6%) or serum CA125 (87.1% vs. 61.2%) in staging OC. Conclusion: LMR alone or in combination with serum CA125 might be associated with OC staging. Besides, as a predictive factor, COLC may have a high specificity in staging OC.
引用
收藏
页码:5923 / 5928
页数:6
相关论文
共 50 条
  • [41] Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer
    Duan, Hongyuan
    Liu, Xiaomin
    Zhang, Yu
    Liu, Ya
    Ji, Yuting
    Zhang, Yunmeng
    Fan, Zeyu
    Liu, Siwen
    Yang, Lei
    Xu, Tingting
    Tian, Jing
    Li, Weiqin
    Lyu, Zhangyan
    Song, Fangfang
    Song, Fengju
    Huang, Yubei
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [42] Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Kang, Sokbom
    Kim, Tae-Joong
    Seo, Sang-Soo
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Park, Sang-Yoon
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 18 - 22
  • [43] Diagnostic value of serum CA125 combined with PET/CT in ovarian cancer and tuberculous peritonitis in female patients
    Wang, Peng
    Feng, Yawen
    Qi, Hongyan
    Feng, Hui
    Chen, Yuqi
    Zeng, Guoliang
    Dai, Wenli
    ABDOMINAL RADIOLOGY, 2023, 48 (11) : 3449 - 3457
  • [44] Nadir CA-125 Level Is an Independent Prognostic Factor in Advanced Epithelial Ovarian Cancer
    Kang, Sokbom
    Seo, Sang-Soo
    Park, Sang-Yoon
    JOURNAL OF SURGICAL ONCOLOGY, 2009, 100 (03) : 244 - 247
  • [45] Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Zhang, Dan
    Jiang, Yu-xia
    Luo, Shu-juan
    Zhou, Rong
    Jiang, Qing-xiu
    Linghu, Hua
    CLINICA CHIMICA ACTA, 2018, 484 : 32 - 35
  • [46] Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Zivanovic, Oliver
    Sima, Camelia S.
    Iasonos, Alexia
    Bell-McGuinn, Katherine M.
    Sabbatini, Paul J.
    Leitao, Mario M.
    Levine, Douglas A.
    Gardner, Ginger J.
    Barakat, Richard R.
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (02) : 209 - 214
  • [47] Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer
    Gemer, O
    Segal, S
    Kopmar, A
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (06) : 583 - 585
  • [48] Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model
    Wang, Haixia
    Liu, Pingping
    Xu, Hai
    Dai, Hongmei
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (12): : 14141 - 14148
  • [49] PREDICTIVE VALUE OF THE COMBINATION OF SERUM MARKERS, CA125, CASA AND TPS IN OVARIAN-CANCER
    DEVINE, PL
    MCGUCKIN, MA
    QUIN, RJ
    WARD, BG
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1995, 5 (03) : 170 - 178
  • [50] Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer
    Jordens, Christopher F. C.
    Morrell, Bronwen
    Harnett, Paul
    Hobbs, Kim
    Mason, Catherine
    Kerridge, Ian H.
    SOCIAL SCIENCE & MEDICINE, 2010, 71 (09) : 1548 - 1556